Ad-hoc News

23.02.2011

The German biotechnology company MOLOGEN AG revealed in Berlin today that the European Patent Office has announced that it will be granting a European patent for the company’s allogenic tumor therapy. The patent protects the cell-based gene therapy...

01.02.2011

  • The gross proceeds total around 10 million Euros
  • This will make company goals attainable
MOLOGEN AG announces today that all its new shares have been issued. The capital increase can take place now in its entirety.

25.01.2011

MOLOGEN AG is announcing today that the purchase price has been set for the new shares that are being offered as part of the purchase offer of up to 1,245,927 new shares in the company from the authorized capital 2010. These are being offered in...

13.01.2011

The Board of Directors of MOLOGEN AG (ISIN: DE 000 663 720 0) decided today with the approval of the Supervisory Board to use the existing authorized capital 2010 in accordance with Para. 4 section 3 of the Articles of Association and to carry out a...

       

Share Subscription Facility with US investor GCF

Further Information

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com